Neuromodulation in COVID-19 Patients
COVID-19
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring SARS-CoV-2, transcranial direct current stimulation (tDCS), executive function, depression, anxiety, autonomic nervous system, motor function
Eligibility Criteria
Inclusion Criteria:
- suspected or confirmed diagnosis for SARS-CoV-2;
- ability to understand and execute the proposed protocol;
- vital signs (body temperature <38ºC, blood pressure between 90 x 60mmHg and 140 x 90 mmHg, respiratory rate between 12 e 30 bpm).
Exclusion Criteria:
- dyspnea or signs of respiratory effort;
- SpO2 ≤ 90%;
- hemodynamic instability;
- deep vein thrombosis, active bleeding, use of cardiac pacemaker;
- injury, pain or metallic implants in the cranium or scalp;
- seizure history;
- suspected or confirmed pregnancy;
- concomitant or previous rheumatic or neurological diseases;
- severe psychiatric diseases (schizophrenia, bipolar disorder, intellectual disability);
- severe musculoskeletal and/or integumentary disorders;
- severe psychiatric disorders;
- severe liver or kidney disease.
Sites / Locations
- D'Or Institute for Research and Education (IDOR)
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Sham Comparator
tDCS-SMA
tDCS- DLPFC
tDCS- SHAM
Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the supplementary motor area (SMA) for 30 minutes.
Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC) for 30 minutes.
Participants randomized to this arm will receive a single session of Sham tDCS for 30 minutes, delivered to supplementary motor area (SMA) or to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC).